
Bradley Mills, Ph.D., and Scott Gerber, Ph.D., in the Gerber Lab
Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away.
The result is that the combination treatment also destroyed pancreatic cells that had spread to the liver, a common site for metastatic disease.
The journal Cell Reports published the study, with Scott Gerber, Ph.D., as corresponding author, and Bradley Mills, Ph.D., a post-doctoral fellow in the Gerber Lab, as first author. They led a large team of collaborators from the University of Rochester departments of Surgery, Microbiology and Immunology, Pathology and Laboratory Medicine, Radiation Oncology, and Environmental Medicine.
Pancreatic cancer is aggressive and generally has poor survival odds. It’s been in the news this year after “Jeopardy!” host Alex Trebek went public with his diagnosis and treatment. In more than 80 percent of patients, the cancer is discovered in later stages when surgery is not an option and chemotherapy is usually not effective beyond stabilizing the disease.
Pancreatic tumors are notoriously hard to treat because they are surrounded by a toxic stew of proteins and other tissues that protect the cancer cells from the immune system’s natural role to attack invaders.
Wilmot researchers looked for an innovative treatment combination that could do two things at once: activate T-cells to attack the cancer and convert the immune-suppressing cells into fighters, the study said.
The combination they used in laboratory models consisted of stereotactic body radiotherapy (SBRT), which delivers high doses of radiation over a short period of time and may also prime the immune system to kill cancer cells; and interleukin-12 (IL-12), which has well-known anti-cancer activity and also activates the immune system. However, IL-12 often comes with harsh side effects. To solve that problem, researchers are testing a timed-release technology in a specially designed mouse model for pancreatic cancer, which would slowly deliver the drug over two weeks.
The preclinical laboratory investigation resulted in Gerber’s team receiving a $2 million National Cancer Institute grant in July to continue the research, which includes moving the findings into clinical trials in the future. Gerber is an assistant professor and co-director of the Center for Tumor Immunology Research.
Learn more: Study: Innovative Pancreatic Cancer Treatment May Rev Up Immune System
The Latest on: Pancreatic cancer treatment
via Google News
The Latest on: Pancreatic cancer treatment
- Novel protein may improve safety of therapy for pancreatic canceron January 22, 2021 at 11:31 pm
Researchers have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell t ...
- Researchers identify protein that may represent a safer treatment target for pancreatic canceron January 22, 2021 at 7:44 pm
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.
- Novel target identified that could improve safety of therapy for pancreatic canceron January 22, 2021 at 7:52 am
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the ...
- Researchers identify novel target that could improve the safety of CAR T cell therapy for pancreatic canceron January 22, 2021 at 6:51 am
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the ...
- Human pancreatic cancer model offers new opportunities for testing drugson January 22, 2021 at 5:50 am
UNSW scientists have grown human pancreatic cancer tumors in the lab—their model is the first of its kind, with important future clinical implications.
- Preop Chemo Misses Mark in Pancreatic Canceron January 21, 2021 at 8:02 am
Two different preoperative chemotherapy regimens for pancreatic cancer failed to improve survival as compared with historical outcomes with adjuvant therapy, a randomized trial showed. A modified ...
- Preop RT Flunks Test in Borderline Pancreatic Canceron January 20, 2021 at 10:32 am
Neoadjuvant chemoradiation failed to improve survival in borderline-resectable pancreatic cancer as compared with chemotherapy alone, a randomized trial showed. Patients randomized to chemotherapy ...
- Pancreatic Cancer Therapy Market 2020 to 2025: Size Expected to Reach US$ 4056.4 million by 2025 Rising at a CAGR of 8.1%on January 19, 2021 at 8:55 pm
Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the ...
- Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patientson January 18, 2021 at 10:30 am
Propanc receives interest to evaluate proenzyme therapy as a way to prevent recurrence & metastasis of solid tumors in pancreatic & ovarian cancers.
- Pancreatic Cancer Market Overview, Sales Revenue, Opportunities, Size, Share, Competitive Landscape and Comprehensive Research Study 2024on January 17, 2021 at 3:14 am
By Type (Endocrine Pancreas Cancer and Exocrine Pancreas Cancer), Treatment (Hormone Therapy, Biologic Therapy, and Targeted Therapy), End User (Hospitals & Clinics and Research Institute) - Global ...
via Bing News